BackOrtho Clinical Diagnostics Holdings plc Overview

Ortho Clinical Diagnostics Holdings plc Operating Income

Latest operating income for OCDX: $160M.

Get informed when a big investor buys or sells

+ Follow

Quarterly Operating Income

$49.20M
14.29% YoY

As of Apr 3, 2022

Annual Operating Income (TTM)

$161.90M
21% YoY

Trailing 12 months ending Apr 3, 2022

Average Operating Income (Comparison Companies)

Operating Income History

Operating Income Comparison

Annual Operating Income Growth Rate (%)

Annual Operating Income Growth (Absolute)

Ortho Clinical Diagnostics Holdings plc (OCDX) FAQ

Ortho Clinical Diagnostics Holdings plc posts a operating income of $160M as of April 2022. That compares with $130M in the prior-year period — up 21.0% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Ortho Clinical Diagnostics Holdings plc's operating income was $130M. The latest reading is $160M — a 21.0% year-over-year increase (period ending April 2022). Use the history and growth charts on this page for a longer lookback.

Operating Income is one piece of Ortho Clinical Diagnostics Holdings plc's financial statement story. At $160M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for OCDX's operating income usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; Ortho Clinical Diagnostics Holdings plc's other metric pages and overview cover the third.

Judging Ortho Clinical Diagnostics Holdings plc against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in operating income easier to interpret. Start with $160M here, then scan peer and history charts to see if the gap is persistent.